CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

The current analysis reconfirms the excellent safety and tolerability profile with no dose-limiting toxicity observed and no grade 4 or 5 treatment emergent adverse events (TEAE).